IL-7 种系变异：为免疫相关不良事件奠定基础。
IL-7 germline variant: setting the stage for immune-related adverse events.
机构信息
Université Côte d'Azur, INSERM, C3M, Nice, France.
Equipe Labellisée Ligue Contre le Cancer, Nice, France.
出版信息
Mol Oncol. 2023 Mar;17(3):384-386. doi: 10.1002/1878-0261.13392. Epub 2023 Feb 24.
Abstract
Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune-related adverse events (irAEs). A new study identified an interleukin 7 (IL-7) allelic variant-rs16906115-as a major risk factor for the development of ICI-associated irAEs. This association is of great significance as it indicates that germline genetic variants influence the occurrence of irAEs, thus opening a new avenue for identifying high-risk patients to enable better management of ICI therapy and associated irAEs.
摘要
免疫检查点抑制剂（ICIs）的治疗常伴有免疫相关不良反应（irAEs）。一项新的研究发现白细胞介素 7（IL-7）等位基因变异体 rs16906115 是 ICI 相关 irAEs 发展的主要危险因素。这一关联具有重要意义，因为它表明种系遗传变异影响 irAEs 的发生，从而为识别高危患者开辟了新途径，以更好地管理 ICI 治疗和相关的 irAEs。
相似文献
1
IL-7 germline variant: setting the stage for immune-related adverse events.IL-7 种系变异：为免疫相关不良事件奠定基础。
Mol Oncol. 2023 Mar;17(3):384-386. doi: 10.1002/1878-0261.13392. Epub 2023 Feb 24.
2
Germline variants associated with toxicity to immune checkpoint blockade.与免疫检查点阻断毒性相关的种系变异。
Nat Med. 2022 Dec;28(12):2584-2591. doi: 10.1038/s41591-022-02094-6. Epub 2022 Dec 16.
3
Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.白细胞介素-10 是预测非小细胞肺癌免疫治疗相关不良反应的有潜力的标志物。
Front Immunol. 2022 Feb 9;13:840313. doi: 10.3389/fimmu.2022.840313. eCollection 2022.
4
Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.血清生物标志物可预测晚期胃肠道癌患者的免疫相关不良事件和临床获益。
Front Immunol. 2022 Sep 8;13:987568. doi: 10.3389/fimmu.2022.987568. eCollection 2022.
5
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.免疫检查点抑制剂的内分泌毒性：一项利用美国食品和药物管理局不良事件报告系统的真实世界研究。
J Immunother Cancer. 2019 Nov 6;7(1):286. doi: 10.1186/s40425-019-0754-2.
6
Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.多器官免疫相关不良事件是癌症患者免疫检查点抑制剂相关性心肌炎的危险因素：一项多中心研究。
Front Immunol. 2022 Jul 18;13:879900. doi: 10.3389/fimmu.2022.879900. eCollection 2022.
7
Association between germ-line HLA and immune-related adverse events.胚系 HLA 与免疫相关不良事件的相关性。
Front Immunol. 2022 Sep 13;13:952099. doi: 10.3389/fimmu.2022.952099. eCollection 2022.
8
Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.医师对免疫检查点抑制剂相关免疫相关不良事件的认知。
J Natl Compr Canc Netw. 2022 Dec;20(12):1316-1320. doi: 10.6004/jnccn.2022.7064.
9
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?免疫检查点抑制剂相关的血液学免疫不良反应，如何管理？
Eur J Cancer. 2019 Nov;122:72-90. doi: 10.1016/j.ejca.2019.07.014. Epub 2019 Oct 18.
10
Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.肠道微生物组和微生物衍生代谢物在免疫相关不良事件中的意义：癌症免疫治疗新型生物标志物的出现。
Int J Mol Sci. 2023 Feb 1;24(3):2769. doi: 10.3390/ijms24032769.
引用本文的文献
1
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment.免疫相关不良事件对晚期胃癌患者免疫检查点抑制剂治疗结局的影响。
Front Immunol. 2024 Dec 24;15:1503316. doi: 10.3389/fimmu.2024.1503316. eCollection 2024.
2
From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events.从肿瘤到耐受：免疫检查点抑制剂及免疫相关不良事件的全面综述
Asia Pac Allergy. 2024 Aug;14(3):124-138. doi: 10.5415/apallergy.0000000000000146. Epub 2024 May 30.
3
Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.接受免疫检查点抑制剂治疗的肺癌患者中免疫相关不良事件的预后相关性：一项系统评价和荟萃分析。
Transl Lung Cancer Res. 2024 Jul 30;13(7):1559-1584. doi: 10.21037/tlcr-24-299. Epub 2024 Jul 12.
本文引用的文献
1
Germline variants associated with toxicity to immune checkpoint blockade.与免疫检查点阻断毒性相关的种系变异。
Nat Med. 2022 Dec;28(12):2584-2591. doi: 10.1038/s41591-022-02094-6. Epub 2022 Dec 16.
2
Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade.与甲状腺自身免疫相关的遗传变异塑造了 PD-1 检查点阻断的系统性免疫反应。
Nat Commun. 2021 Jun 7;12(1):3355. doi: 10.1038/s41467-021-23661-4.
3
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.免疫检查点抑制剂在癌症治疗中的应用：临床影响及反应和耐药的机制。
Annu Rev Pathol. 2021 Jan 24;16:223-249. doi: 10.1146/annurev-pathol-042020-042741. Epub 2020 Nov 16.
4
A decade of immune-checkpoint inhibitors in cancer therapy.免疫检查点抑制剂在癌症治疗中的十年。
Nat Commun. 2020 Jul 30;11(1):3801. doi: 10.1038/s41467-020-17670-y.
5
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
6
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的免疫相关不良事件。
N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.
7
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.抗 CTLA-4 和抗 PD-1 抗体单药及联合治疗的安全性特征。
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4.
8
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
9
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.共生双歧杆菌可促进抗肿瘤免疫并增强抗程序性死亡受体配体1（PD-L1）的疗效。
Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.
10
Pharmacogenetics of cancer drugs.癌症药物的药物遗传学。
Annu Rev Med. 2015;66:65-81. doi: 10.1146/annurev-med-053013-053944. Epub 2014 Oct 29.
Zotero 插件